Dihydromyricetin (DHM)

Dihydromyricetin is a flavonol extracted from Ampelopsis grossedentata (vine tea) and Hovenia dulcis, with two mechanistically distinct arms that happen to converge on the same practical goal: surviving alcohol with less cognitive, hepatic, and metabolic damage. One arm lives in the CNS, the other in the liver and mitochondria — and the supplement is useful even when alcohol isn't in the picture.

GABA-A Benzodiazepine-Site Antagonism#

The Shen 2012 paper in Journal of Neuroscience is the foundational mechanism work. DHM binds competitively at the benzodiazepine site of the GABA-A receptor (IC₅₀ ≈ 4.36 μM) and antagonizes ethanol's allosteric potentiation of GABA-AR currents without itself behaving as a GABA antagonist. Flumazenil abolishes the effect, confirming the BZ-site interaction. Functionally, this blunts ethanol-induced sedation and motor impairment during acute exposure, and — more importantly for the physique-focused audience — dampens the rebound hyperexcitability, anxiety, and sleep fragmentation that characterize the withdrawal phase the morning after.

"DHM antagonized the acute intoxicating effects of alcohol, suppressed withdrawal symptoms, and counteracted alcohol tolerance." — Shen Y. et al., Journal of Neuroscience, 2012

Practical translation: the reduced "hangxiety" and faster cognitive recovery users report is not placebo — it is the GABA-AR arm coming back online as ethanol clears.

Ethanol and Acetaldehyde Clearance#

DHM upregulates both alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH2), accelerating the conversion of ethanol → acetaldehyde → acetate. Acetaldehyde is the toxic intermediate responsible for most of the flushing, nausea, tachycardia, and next-day systemic malaise associated with drinking. Clearing it faster is the hepatic mechanism behind the "anti-hangover" reputation. This arm is also why pre-drink and intra-drink dosing outperforms pure morning-after rescue — the enzymes need to be upregulated while acetaldehyde is actively being generated, not after.

SIRT3-Mediated Mitochondrial and Redox Support#

Independent of alcohol, DHM is a legitimate metabolic and hepatoprotective molecule. The Zeng 2019 work in NAFLD models demonstrated that DHM activates SIRT3 signalling, restores mitochondrial respiratory capacity, reduces ROS production, and lowers hepatic triglyceride accumulation.

"DHM treatment significantly restored mitochondrial function, decreased oxidative stress, and regulated SIRT3-mediated pathways in NAFLD models." — Zeng X. et al., Antioxidants & Redox Signaling, 2019

This translated into hard clinical endpoints in humans. The Chen 2015 RCT in 60 NAFLD patients using 300 mg twice daily for three months produced statistically significant reductions in ALT, AST, GGT, fasting glucose, HOMA-IR, and LDL versus placebo — the same dose range community users run for on-cycle liver support alongside TUDCA and NAC.

GLP-1 Potentiation and Metabolic Signalling#

A more recent mechanism, and one that matters for recomp-oriented users. Wu 2022 demonstrated that DHM enhances exercise-induced GLP-1 secretion by raising intracellular cAMP and inhibiting DPP-4, the enzyme that degrades GLP-1. The effect size is modest — DHM is not a semaglutide substitute — but it plausibly contributes to the improved fasting glucose and insulin sensitivity numbers seen in the NAFLD trial, and it stacks sensibly with training in a cutting context.

"DHM promoted GLP-1 secretion via upregulating cAMP and suppressing DPP-4 activity in exercising mice." — Wu L. et al., Nutrients, 2022

The Bioavailability Problem#

Any mechanistic discussion has to end here, because it dictates dosing reality. Liu 2017 measured oral bioavailability in rats at roughly 4%, with Tmax near 2.5–3 hours and an oral half-life around 3.7 hours. Poor aqueous solubility, rapid Phase II glucuronidation, and efflux transport all conspire against raw DHM powder. The practical consequence is that formulation dominates dose: phospholipid complexes, micronized preparations, and lipid-based delivery systems produce meaningfully better plasma exposure than bulk 98% powder, which is why community-preferred products (micronized or phospholipid-formulated) consistently outperform cheap Alibaba material at the same label dose. Users who write DHM off as ineffective have almost always tested it as raw powder at 300 mg — the floor of a dose range that probably needs to start at 500–600 mg of a formulated product to feel anything.

Bottom line: DHM is a two-armed compound — a GABA-AR gatekeeper on the acute side, a SIRT3/ADH/ALDH2 workhorse on the chronic side — whose real-world ceiling is set almost entirely by how well the formulation gets it into plasma.

Common (most users)#

• Mild nausea or loose stools — almost always dose- and formulation-dependent. Most commonly reported at single doses above 1 g of raw, unformulated powder. Splitting the dose (e.g. 500mg pre-drink + 500mg pre-bed rather than 1g at once) or switching to a phospholipid-complexed / micronized formulation resolves it in the large majority of cases. Administration with a small amount of dietary fat improves absorption and reduces GI complaints simultaneously.
• Headache or lightheadedness — typically reported when DHM is stacked with alcohol and inadequate fluid intake. Mitigation is mechanical: 500mL water plus electrolytes (sodium, potassium, magnesium) alongside each DHM dose during drinking windows.
• Subjectively "nothing happened" — the most common complaint, and almost always a bioavailability problem rather than a pharmacology problem. Oral bioavailability sits near 4% for raw powder. Users running bulk 98% powder frequently need roughly double the dose of users running phospholipid-formulated products to match subjective effect. Fix the formulation before concluding the molecule doesn't work.
• Mildly lower fasting glucose — DHM promotes GLP-1 secretion via cAMP upregulation and DPP-4 suppression in the Wu 2022 exercising-mouse model, and the Chen 2015 NAFLD RCT showed reduced fasting glucose and HOMA-IR at 300mg BID over 12 weeks. For most physique-focused users this is a feature, not a side effect, but it is worth being aware of in a fasted state.

"Oral supplementation with 300 mg DHM twice daily for 3 months significantly reduced serum ALT, AST, GGT, fasting glucose, and LDL cholesterol versus placebo." — Chen et al., Pharmacological Research (2015)

Uncommon (dose-dependent or individual)#

• GI upset at single doses >1 g — back off to 500–600mg per dose and split across the drinking window instead of front-loading. A phospholipid or self-emulsifying formulation tolerates high single doses better than raw powder.
• Blunted response to prescribed benzodiazepines or Z-drugs — DHM competitively occupies the benzodiazepine site on GABA-A (IC₅₀ ≈ 4.36 μM in the Shen 2012 work) and, in rodent models, antagonized ethanol potentiation of GABA-AR currents without being a GABA antagonist itself. Mechanistically, the same site-binding behavior can reduce the subjective potency of prescribed BZDs or zolpidem-class hypnotics dosed in the same window. Users on chronic benzodiazepine therapy should separate dosing or avoid the combination.
• Additive glucose-lowering when stacked with aggressive GLP-1 agonists or insulin — not a deal-breaker, but worth flagging. On a semaglutide/tirzepatide protocol running 600mg+ DHM daily, monitor fasting glucose and symptomatic hypoglycemia.
• LDL / LFT non-response — if the NAFLD-style 300mg BID × 12-week protocol is run and ALT, AST, GGT, and lipid panel show no movement at retest, the issue is usually formulation (raw powder, low-COA vine tea extract at 40–60% purity rather than 98%) rather than protocol. Verify COA, switch to a formulated product, and reassess at a further 8 weeks.

"DHM promoted GLP-1 secretion via upregulating cAMP and suppressing DPP-4 activity in exercising mice." — Wu et al., Nutrients (2022)

Rare but serious#

• No hepatotoxicity signal in the published record. Unlike high-dose green tea catechins (EGCG), DHM has not produced idiosyncratic liver injury reports in the clinical or case-report literature. The Chen 2015 RCT reported no significant adverse events at 600mg/day for 3 months.
• No cardiovascular signal. Blood pressure, heart rate, and ECG endpoints were not adversely affected in the NAFLD RCT.
• Theoretical CNS over-dampening when combined with other GABAergics (alcohol + phenibut + benzodiazepines + DHM stacks have been reported anecdotally). The GABA-AR pharmacology here is nuanced — DHM antagonizes ethanol's potentiation rather than adding sedation — but poly-GABAergic stacking is the scenario where unexpected interactions would be most likely to appear. Warning signs: disproportionate sedation, paradoxical anxiety on waking, or memory gaps beyond what the ethanol dose would predict. Discontinue the stack and reassess dosing.

Hard contraindications#

• Pregnancy and lactation — no human safety data exist. Do not use.
• Chronic benzodiazepine or Z-drug therapy — BZ-site competition makes this a pharmacodynamic conflict, not a safety emergency, but the interaction is real and dosing schedules should not overlap without clinical oversight.
• "License to drink more" framing — DHM blunts the subjective intoxication signal and accelerates acetaldehyde clearance. It does not meaningfully lower blood alcohol concentration, does not make operating a vehicle after drinking safe, and does not neutralize the organ toxicity of heavy chronic ethanol intake. Users who treat DHM as permission to drink past their normal limit routinely present with creeping ALT/AST despite the protocol. This is the single most common way the compound gets misused.

Gender and cycle considerations#

No gender-specific dose adjustment. DHM is not hormonally active, does not suppress the HPTA, does not aromatize, and carries no virilization or gynecomastia risk — it is equally usable by male and female physique-focused users. No PCT considerations apply. For users stacking DHM onto oral AAS cycles as part of a hepatoprotective triad (DHM 300mg BID + TUDCA 250–500mg/day + NAC 600–1,200mg/day), standard on-cycle LFT monitoring every 4–6 weeks remains the correct cadence — the DHM arm supplements, rather than replaces, cycle length discipline and sensible oral dosing.